Anesthetic-Induced Disruption of Amino Acid and Carnitine Profiles: A Metabolomic Comparison of Propofol and Thiopental in Hepatocytes
<b>Background/Objectives:</b> Propofol and Thiopental are widely used anesthetic agents, yet their cumulative and high-dose effects on hepatic metabolism remain insufficiently characterized. This study aimed to evaluate the impact of supra-therapeutic concentrations of these agents on carnitine and amino acid metabolism in AML12 hepatocytes, with a focus on their toxicometabolic profiles. <b>Methods:</b> AML12 mouse hepatocytes were exposed to escalating concentrations (2.5-500 µg/mL) of Propofol and Thiopental to assess cytotoxicity. IC<sub>50</sub> values (~255 µg/mL for both) were determined, and two high-dose concentrations (100 µg/mL and 200 µg/mL) were selected for metabolic profiling. Cell viability was assessed via the MTT assay. Intracellular carnitine and amino acid levels were quantified using LC-MS/MS. Statistical analyses included one-way ANOVA with post hoc tests, unpaired <i>t</i>-tests, and effect size estimations (Cohen's d). <b>Results:</b> Propofol significantly suppressed carnitine metabolism in a dose-dependent manner, with a 79% reduction in free carnitine (C0), indicative of impaired mitochondrial β-oxidation. Thiopental, however, preserved or partially restored several acylcarnitines, including C16:1. While both agents reduced intracellular amino acid levels, 200 µg/mL Thiopental partially restored key metabolites such as glutamine, alanine, and histidine. Propofol exhibited broader metabolic suppression. Effect size analysis further confirmed the stronger inhibitory impact of Propofol. <b>Conclusion:</b> Although the concentrations used exceed typical clinical plasma levels, they may reflect prolonged or high-dose exposure scenarios observed in ICU settings. The findings highlight distinct toxicometabolic signatures for each agent and underscore the utility of metabolite profiling in modeling anesthetic-induced hepatic stress and guiding anesthetic selection in vulnerable populations.
Authors
- Başak Pehlivan (ORCID: https://orcid.org/0000-0001-6985-343X)
- Erdoğan Duran (ORCID: https://orcid.org/0000-0002-9606-8266)
- Veli Fahri Pehlivan (ORCID: https://orcid.org/0000-0001-5661-4499)
- Hamza Erdoğdu (ORCID: https://orcid.org/0000-0002-5025-2367)
- Ismail Koyuncu
Institutions
- Türk Anesteziyoloji ve Reanimasyon Derneği (TR)
- Harran University (TR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-08-19
- DOI
- https://doi.org/10.3390/ph18081221
- Citations
- 1
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Harran Üniversitesi